Table 1.

Volunteer demographic data, doses of intravenous midazolam and the number of 500 mg oral clarithromycin tablets received prior to each endoscopy

Subject	Sex	Race	CYP3A5 genotype	Age (years)	Midazolam dose (mg)				Consecutive clarithromycin tablets
					E1	E2	E3	E4	E1	E2	E3	E4
1	F	White	*3/*3	24	4	6	6	8	0	1	6	12
2	M	White	*3/*3	35	2	6	7	8	0	1	4	12
3	M	Black	*3/*6	26	5.5	8	7	10	0	1	2	12
4	M	Black	*1/*1	32	6	6	4	6	0	1	5	13
5	F	White	*3/*3	25	7	8	10	10	0	1	5	13
6	F	White	*3/*3	22	8	10	10	10	0	1	2	12
7	F	White	*3/*3	25	10	8	10	10	0	1	2	12
8	M	Black	*1/*1	48	7	6	6	10	0	1	2	12
9	M	White	*3/*3	30	10	9	8	8	0	1	2	12
10	M	White	*3/*3	25	8	10	10	10	0	1	2	10
11	F	White	*1/*3	24	8	8	10	10	0	1	2	10
12	F	Black	*1/*3	37	10	10	10	10	0	3	5	15

CYP3A5, Cytochrome P450 3A5; E1, E2, E3, E4, first, second, third, fourth endoscopy, respectively; F, female; M, male